Effect of Combination Therapy on Visible/Non-Visible Symptoms, and Disease Burden Associated with Severe Rosacea: Results from A Post-Hoc Analysis of A Randomized Controlled Trial

Main Article Content

James Q Del Rosso
Mark Jackson
Sandra Johnson
Alison Harvey
Rajeev Chavda

Keywords

Rosacea, disease burden, combination therapy

Abstract

Abstract not available.

References

1. Steinhoff M, Schmelz M, Schauber J. Facial erythema of rosacea - aetiology, different pathophysiologies and treatment options. Acta Derm Venereol. 2016;96(5):579–586.

2. Schaller M, Almeida LMC, Bewley A, et al. Recommendations for rosacea diagnosis, classification and management: Update from the global ROSacea COnsensus (ROSCO) 2019 panel. Br J Dermatol. August 2019. [Epub ahead of print]

3. National Rosacea Society Website. https://www.rosacea.org/rosacea-review/2010/winter/rosacea-now-estimated-to-affect-at-least-16-million-americans. Accessed November 21, 2019.

4. Tan J, Steinhoff M, Bewley A, Gieler U, Rives V. Characterizing high-burden rosacea subjects: a multivariate risk factor analysis from a global survey. J Dermatolog Treat. June 2019. [Epub ahead of print]

5. Schaller M, Kemeny L, Havlickova B, et al. A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40 mg modified-release capsules versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea. J Am Acad Dermatol. May 2019. [Epub ahead of print]